Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib Plus Chemotherapy in EGFR TKI-Responsive NSCLC
NCT00660816Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jan 2008
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Case Comprehensive Cancer Center. Started Jan 2008; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00660816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00660816.